Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017148595) TITRATION OF CEBRANOPADOL
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/148595 International Application No.: PCT/EP2017/025034
Publication Date: 08.09.2017 International Filing Date: 28.02.2017
IPC:
A61K 31/407 (2006.01) ,A61P 25/00 (2006.01)
[IPC code unknown for A61K 31/407][IPC code unknown for A61P 25]
Applicants:
GRÜNENTHAL GMBH [DE/DE]; Zieglerstraße 6 52078 Aachen, DE
Inventors:
WANG, Shaonan; DE
PIANA, Chiara; IT
BURSI, Roberta; NL
Priority Data:
16020302.211.08.2016EP
16157868.729.02.2016EP
Title (EN) TITRATION OF CEBRANOPADOL
(FR) TITRAGE DE CÉBRANOPADOL
Abstract:
(EN) The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.
(FR) L'invention concerne l'utilisation de Cébranopadol dans le traitement de la douleur, le Cébranopadol étant administré selon un régime d'administration comprenant : (i) un premier intervalle d'administration, qui dure au moins 2 jours consécutifs, une première dose quotidienne de Cébranopadol étant administrée chaque jour du premier intervalle d'administration; et (ii) un second intervalle d'administration, qui dure au moins 2 jours consécutifs et suit directement le premier intervalle d'administration sans interruption, une seconde dose quotidienne de Cébranopadol étant administrée chaque jour du second intervalle d'administration; la première dose quotidienne de Cébranopadol étant inférieure à la seconde dose quotidienne de Cébranopadol.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)